Discovery: The Soul of Biotech, the Place For True Believers, and a Retro Way to Bring it Back


Xconomy Seattle — 

Not so long ago, there was a day when biotechnology companies were built to last. They were founded and directed by pioneering scientists who were courageous, true-believers in their respective technologies. Their drive, creative spirit, and dedication to discovery positioned their companies in ways that could create multiple opportunities for success in therapeutic discovery and development. Here in Seattle, companies like Immunex, Icos and Seattle Genetics represented some of the last companies in our area formed with such intentions. Years after the founding of these companies, our industry changed dramatically after the “contraction” of 2001 where virtually all biotechs cut or eliminated discovery in favor of pushing forward late and later stage drugs (a market-induced effect as cash sources mysteriously dried up). The mantra at the time was, “we can always buy the drugs later when we need them.”

There was a also a day when your board of directors was “in it for the long haul.” I can recall George Rathmann, the co-founder of Icos, describing this attribute to a reporter, stressing its importance and necessity for success. The board of directors in those days set the example of investing and growing their companies to profitability – a painful process that can take an average of 10 to 12 years. Upon founding Spaltudaq, this is what I expected because it was all that I knew. I was confused when someone early on in the days of Spaltudaq asked me, “What’s your exit strategy?” I thought it was a trick question. “I’m still working on my entrance,” I responded. My startup carrots were given in the form of milestone achievement. Like the founders of old, my intentions were to spend the time to expand and take advantage of a versatile technology designed to create endless opportunities for creating LONG term value.

But in this decade, the way companies are started is much different. Instead of building the next Amgen, Genentech, or any other company with a long-term minded board of directors, the investors of today want the exact opposite. They want in and out at clearly defined exit points—going public or getting bought out. This is understandable given the number of investors that got burned in the 10 to 12-year plans of the past where about 1 in 10 companies succeeded. But the reflexive overreaction to those days has created a system of growing companies that today is inversely related to the spirit of discovery that got our industry here in the first place. And as a result, this plan is diametrically opposed to the intentions of most scientific founders whose vision is vectorial – and not with an “exit” in mind.

How has this happened?

Just like systems biology, perturbations in the market give rise to new emerging properties and investors react. For the most part in this decade, it has become obvious that biotech companies will give the greatest return for their investors if the company is purchased rather than the prior exit point, “going public”. Antibody companies are a classic example as they have been rapidly taken out for an average price of $500 million, whereas going public would only bring about one-third of that value.

The war on discovery:

Why are companies rapidly getting bought out and how does this affect drug discovery and growth in our industry locally? … Next Page »

Single PageCurrently on Page: 1 2 3 4

Johnny Stine is founder and president of North Coast Biologics, a Seattle-based company that discovers targeted antibody drugs. Follow @

Trending on Xconomy

By posting a comment, you agree to our terms and conditions.

One response to “Discovery: The Soul of Biotech, the Place For True Believers, and a Retro Way to Bring it Back”

  1. It seems every biotech these days wants to be the next Immunex, Amgen, or Genentech, but they run from the very thought of following the same path as these successful enterprises! You are exactly right that the current model for big pharma and biotech is unsustainable, and that new solutions are needed. I’m always amazed when I meet someone at a new biotech company, ask them about their research program, and find out that they don’t have one! Instead, they have licensed some protein or target from a University and are moving into the clinic with only the foggiest understanding of the biology involved. Their mission: get clinical data ASAP. It’s no wonder that these companies are flaming out at such a rapid rate! The VC model at present seems to have been modeled at the casinos in Vegas. I consulted once for a biotech that was a one-trick pony. The whole company was riding on a single molecule, but the biological basis for the action of this molecule had been completely misinterpreted. When I pointed this out to them, they decided to move ahead anyway,since they had no substitute at hand and had been funded to put THAT molecule into the clinic. Their subsequent demise was completely predictable. While it would be nice if your technology is as cheap and powerful as you believe, not all biological problems can be solved with monoclonal antibodies, so additional paradigm shifters will be needed as well. Finally, I wish we had only lost 500 jobs in the local biotech arena since 2002. I’ve actually kept track of the numbers, and the real total is over 2200! That’s a lot of critical mass that has left town due to a lack of replacement jobs. We still have a long way to go to get ourselves back to where we were even six years ago.